Drug Patents owned by Averitas

1. List of Qutenza drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10869827 AVERITAS Compositions and kits for the removal of irritating compounds from bodily surfaces
Sep, 2023

(5 months from now)

US8263059 AVERITAS Compositions and kits for the removal of irritating compounds from bodily surfaces
Sep, 2023

(5 months from now)

US8889113 AVERITAS Compositions and kits for the removal of irritating compounds from bodily surfaces
Sep, 2023

(5 months from now)

US10463598 AVERITAS Compositions and kits for the removal of irritating compounds from bodily surfaces
Sep, 2023

(5 months from now)

US10034841 AVERITAS Transdermal therapeutic system comprising an adhesive layer method for siliconizing the back layer of the system and use of said back layer
Sep, 2025

(2 years from now)

US9226903 AVERITAS Transdermal therapeutic system comprising an adhesive layer method for siliconizing the back layer or the system and use of said back layer
Dec, 2028

(5 years from now)

US8821920 AVERITAS Therapeutic patch for transdermal delivery of capsaicin
Mar, 2030

(7 years from now)

Exclusivity Exclusivity Expiration
New Indication (I) Jul 17, 2023

Drugs and Companies using CAPSAICIN ingredient

Market Authorisation Date: 16 November, 2009

Treatment: Method of using capsaicin in combination with a gel composition for removal of capsaicin from a treatment area or unintended area

Dosage: PATCH;TOPICAL

More Information on Dosage

QUTENZA family patents

19

United States

6

European Union

4

Portugal

4

Spain

4

China

4

Canada

4

Japan

4

Slovenia

4

Denmark

3

Mexico

3

Cyprus

3

Poland

3

Australia

2

Germany

2

Russia

2

Brazil

2

New Zealand

2

Korea, Republic of

2

Hong Kong

2

South Africa

2

Lithuania

2

Israel

1

Norway

1

Argentina

1

Austria

1

Taiwan, Province of China

1

EA

1

Hungary

1

Ukraine

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic